D.J.A. Lobbezoo

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd et al. · Breast Cancer Research and Treatment · 2013 · 250 citations

Medicine, Cancer Biology, Oncology +16

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd et al. · British Journal of Cancer · 2015 · 242 citations · Full text

Medicine, Biostatistics, Oncology +17

In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium

D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd et al. · Annals of Oncology · 2015 · 81 citations · Full text

Medicine, Oncology, Chemotherapy +16

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium

Shanly C. Seferina, D.J.A. Lobbezoo, Maaike de Boer et al. · The Oncologist · 2015 · 36 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

Roel J.W. van Kampen, Bram Ramaekers, D.J.A. Lobbezoo et al. · European Journal of Cancer · 2017 · 20 citations

Medicine, Oncology, Pharmacoeconomics +16